In conclusion, we demonstrated that the detection of the BRAF and NRAS cfDNA status with the IdyllaTM assay is feasible in a routine manner in a pathology laboratory, before and after systemic treatment of patients with metastatic melanoma. The gene discussed is BRAF; the disease is metastatic melanoma.